Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bi-44370. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL known ✓ | Q16602 | 20/20 | 1.00 |
| ▸ | RAMP1 | O60894 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bi-44370 SCHEMBL29644516 | 1.00 | CALCRL (1.00) | CALCRLRAMP1CYP3A4 | |
| Bi-44370 SCHEMBL2088322 | 1.00 | CALCRL (1.00) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL2166657 | 0.96 | CALCRL (0.92) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL2166662 | 0.96 | CALCRL (0.92) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL13712916 | 0.95 | CALCRL (0.91) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL13712917 | 0.94 | CALCRL (0.90) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL14016414 | 0.94 | CALCRL (0.90) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL12773023 | 0.94 | CALCRL (0.89) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL2164024 | 0.94 | CALCRL (0.88) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL2164025 | 0.94 | CALCRL (0.88) | CALCRLRAMP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719347-A1 | SPRAY-DRIED COMPOSITIONS COMPRISING CGRP RECEPTOR ANTAGONISTS | Orexo AB (SE) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024246541-A1 | SPRAY-DRIED COMPOSITIONS COMPRISING CGRP RECEPTOR ANTAGONISTS | OREXO AB (SE) | 2024-12-05 | — | — | WO | disclosed |
| EP-1992349-B1 | CGRP antagonists, their preparation and use as a medicament | BOEHRINGER INGELHEIM INT (DE) | 2013-07-31 | — | — | EP | disclosed |
| US-8288531-B2 | Preparation process | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| US-8288531-B2 | Preparation process | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| US-8119797-B2 | Production method | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8119797-B2 | Production method | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8084634-B2 | Production method | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-8084634-B2 | Production method | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20110295000-A1 | PRODUCTION METHOD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20080086003-A1 | 1-[4-amino-3,5-dibromo-N-[[4-(2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine-p-toluenesulphonate or other inorganic organic salts; calcitonin gene related peptide-antagonist; useful for treating headache and migraine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-10 | — | — | US | disclosed |
| US-20080086003-A1 | 1-[4-amino-3,5-dibromo-N-[[4-(2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine-p-toluenesulphonate or other inorganic organic salts; calcitonin gene related peptide-antagonist; useful for treating headache and migraine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-10 | — | — | US | disclosed |
| WO-2008022962-A2 | METHOD FOR PRODUCING N-PIPERIDINYL-BENZODIAZEPINES HAVING CGRP-ANTAGONISTIC PROPERTIES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
| US-20080045705-A1 | Production Method | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045705-A1 | Production Method | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| WO-2007141285-A1 | TREATMENT OF GASTROINTESTINAL DISORDERS WITH CGRP-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007118819-A2 | NOVEL CRYSTALLINE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007036532-A2 | SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-05 | — | — | WO | disclosed |
| US-20070072847-A1 | -(4-Hydroxy-3,5-dimethyl-benzyl)-2-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate; headaches; non-insulin dependent diabetes; antidiabetic agents; cardiovascular/nervous system disorders; antiinflammatory agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-29 | — | — | US | disclosed |
| US-20060252750-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072847-A1 | -(4-Hydroxy-3,5-dimethyl-benzyl)-2-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate; headaches; non-insulin dependent diabetes; antidiabetic agents; cardiovascular/nervous system disorders; antiinflammatory agents | GPR119, HTR1D, TRPV1 | CALCRL 9/4885RAMP1 55/4885CYP3A4 664/4885 |
| US-20080045705-A1 | Production Method | CYP2F1, CYP7A1, CYP1A1 | CALCRL 2108/4885RAMP1 636/4885CYP3A4 28/4885 |
| US-20080086003-A1 | 1-[4-amino-3,5-dibromo-N-[[4-(2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine-p-toluenesulphonate or other inorganic organic salts; calcitonin gene related peptide-antagonist; useful for treating headache and migraine | SUCNR1, TRPC1, TRPV1 | CALCRL 10/4885RAMP1 629/4885CYP3A4 2589/4885 |
| US-20060252750-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 92/4885CYP3A4 1182/4885 |
| US-20110295000-A1 | PRODUCTION METHOD | CYP2F1, CYP7A1, CYP1A1 | CALCRL 2108/4885RAMP1 636/4885CYP3A4 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.